However, in clinical trials, SGLT-2i improved cardiovascular and kidney outcomes in patients with or without type 2 diabetes [10,25,26], and similar results were observed with the use of GLP-1 RAs in the setting of type 2 diabetes or obesity [14,23,27,28,29,30]. Here, GLP1R is linked to obesity disorder.